Post transplant lymphoproliferative disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Post transplant lymphoproliferative disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure https://clinicaltrials.eu/trial/study-of-tabelecleucel-for-patients-with-epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-after-transplant-treatment-failure/ Wed, 29 Apr 2026 14:58:57 +0000 https://clinicaltrials.eu/trial/study-of-tabelecleucel-for-patients-with-epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-after-transplant-treatment-failure/ This clinical trial is focused on studying a condition known as Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD). This disease can occur in patients who have undergone organ or cell transplants and is associated with the Epstein-Barr virus. The study is investigating a treatment called tabelecleucel, also known by its code name ATA129. Tabelecleucel is a type of cell therapy that uses specially prepared cells to target and fight the virus-related disease.

The purpose of the study is to determine the clinical benefit of tabelecleucel in patients with EBV+ PTLD who have not responded to previous treatments, such as rituximab or rituximab combined with chemotherapy. Participants in the study will receive tabelecleucel through an injection into their veins. The study will monitor how well the treatment works and how the disease responds over time.

Participants will be observed throughout the study to assess the effects of the treatment. The study aims to provide valuable information on the effectiveness of tabelecleucel for patients with EBV+ PTLD, offering insights into potential new treatment options for those who have not had success with existing therapies. The study is expected to continue until 2027, allowing researchers to gather comprehensive data on the treatment’s impact.

]]>